Corcept Therapeutics (CORT) Misses Q1 EPS by 1c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/1/2026

1. INTC
2. AMZN
3. RDDT
4. PINS
5. COIN
6. FSLR
7. SYK
8. DASH
9. MA
10. FND

Go back to Corcept Therapeutics (CORT) Misses Q1 EPS by 1c

Corcept Therapeutics Announces First Quarter 2015 Results and Provides Corporate Update

May 7, 2015 4:06 PM EDT

MENLO PARK, CA -- (Marketwired) -- 05/07/15 -- Corcept Therapeutics Incorporated (NASDAQ: CORT)

Per-share net loss in first quarter narrows to $0.05, from $0.14 in the same period last year First quarter revenue is $10.1 million, compared to $4.4 million in the first quarter 2014, a 129 percent increase $17.2 million generated from exercise of warrants Patient dosing underway in efficacy portion of Phase 1/2 trial of Korlym to treat triple-negative breast cancer (TNBC); results expected by the end of 2015 Next-generation selective GR antagonist CORT125134 is well-tolerated and functionally active in Phase 1 and is expected to enter Phase 2 in... More